GlassScriptPhysician profile
John P Vaclavik
NPI 1548467137
$3,735.80
in general payments reported to CMS, 2019-2025
34 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $272 · 2021: $624 · 2022: $689 · 2023: $435 · 2024: $381 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $799.76 | 2019-2024 | Liletta, Lo Loestrin Fe |
| Celularity INC. | $612.00 | 2019 | |
| Exeltis, USA INC. | $296.17 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $248.97 | 2021-2025 | |
| Daiichi Sankyo INC. | $179.33 | 2021-2024 | Injectafer |
| Evofem Biosciences, INC. | $168.10 | 2020-2025 | Solosec, Phexx, Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $139.68 | 2019-2023 | |
| Astellas Pharma US INC | $129.60 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $116.27 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $97.45 | 2019-2023 | Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $94.76 | 2019-2022 | |
| Sage Therapeutics, LLC | $82.94 | 2024 | |
| Vertical Pharmaceuticals, LLC | $73.78 | 2019 | |
| Organon LLC | $68.28 | 2022-2025 | Nexplanon, Jada System |
| Amgen INC. | $60.90 | 2019-2025 | Evenity |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $59.68 | 2019-2020 | |
| Pfizer INC. | $58.38 | 2023 | |
| Coopersurgical, INC. | $54.09 | 2019-2022 | |
| Myovant Sciences INC. | $44.83 | 2022 | |
| Amag Pharmaceuticals, INC. | $44.20 | 2019-2020 | |
| Scynexis, INC. | $43.83 | 2022 | |
| Avion Pharmaceuticals | $41.43 | 2019-2023 | Balcoltra |
| Coloplast Corp | $36.35 | 2021 | |
| Baudax Bio INC. | $24.99 | 2022 | |
| Dilon Technologies, INC. | $22.70 | 2025 | Hemoblast Bellows |
| Mimedx Group, INC. | $21.28 | 2025 | |
| Roche Diagnostics Corporation | $17.20 | 2021 | |
| Channel Medsystems, INC. | $16.29 | 2024 | |
| Medtronic, INC. | $16.10 | 2022 | |
| Millicent US INC | $15.19 | 2025 | Femlyv |
| Lupin INC. | $14.87 | 2019 | |
| Merck Sharp & Dohme LLC | $14.30 | 2019 | |
| Medicem INC. | $12.39 | 2021 | |
| Heron Therapeutics, INC. | $9.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vaclavik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.